For example, detection of P-STAT1/P-STAT5 or IL-2R expression in liver biopsies was not performed in a sufficiently large number of cells; furthermore, liver biopsies from patients after IL-2 therapy or patients without hepatitis B, or IL-2 treated patients with nonalcoholic fatty liver disease, were not used as controls. This evidence concerns the gene IL2 and metabolic dysfunction-associated steatotic liver disease.